Leading the pharmaceutical frontier in active ingredient synthesis to combat staphylococcal infections in veterinary medicine with unparalleled purity and efficacy.
As a global leader in the Veterinary Pharmaceutical Industry, we specialize in the large-scale synthesis of high-purity active pharmaceutical ingredients (APIs) designed to target resistant staphylococcus strains. Our facility integrates cutting-edge chemical engineering with strict biological safety protocols.
Our technical advantage lies in Stereoselective Synthesis and advanced crystallization techniques, ensuring that every batch of anti-staphylococcal raw material meets USP/EP standards, maximizing therapeutic index while minimizing systemic toxicity in animals.
Our manufacturing process is built upon three fundamental pillars of pharmaceutical science to ensure absolute efficacy.
Data-driven validation of our pharmaceutical potency and market penetration.
Comprehensive chemical analysis of our leading veterinary API, meeting highest global standards.
| Specification | Method | Tolerance | Grade | Result | |
|---|---|---|---|---|---|
| Chemical Purity | ≥ 99.8% | HPLC | ± 0.1% | Pharma | Compliant |
| Moisture Content | ≤ 0.5% | Karl Fischer | ± 0.05% | USP | Passed |
| Heavy Metals | ≤ 10 ppm | ICP-MS | N/A | EP | Passed |
| Particle Size | D90 ≤ 10μm | Laser Diffraction | ± 2μm | Ultra-Fine | Optimized |
| Residual Solvents | ≤ 500 ppm | GC-HS | ± 50 ppm | ICH Q3C | Compliant |
| Melting Point | 155 - 158°C | Capillary | ± 1.0°C | Standard | Confirmed |
| Assay (Dry Basis) | 98.0 - 102.0% | Titration | ± 0.5% | Pharma | Verified |
| Endotoxins | ≤ 0.2 EU/mg | LAL Test | N/A | Sterile | Passed |
Note: All specifications are based on Pharmacopoeia standards (USP/EP/BP). Custom synthesis options are available for specific therapeutic requirements.
How our high-purity raw materials transformed staphylococcal treatment for leading vet-pharma brands.
Implemented our high-purity API to reduce treatment cycles for staphylococcal mastitis by 30%.
Custom micronized powder enabled superior absorption for topical equine staphylococcal creams.
Supplied stable API for injectable formulations, reducing staphylococcal pneumonia rates in large herds.
Developed a specialized low-irritation API for companion animal skin treatments, optimizing healing times.
Supplied high-potency API for treating MRSA in livestock, enhancing overall herd survival rates.
Successfully transitioned a production line to our API, achieving full EU-GMP compliance and zero batch failures.
Our API is the gold standard for various animal health sectors combating bacterial infections.
High-purity APIs for intramammary infusions targeting staphylococcal mastitis in dairy cattle.
Micronized raw materials for high-absorption topical ointments against equine skin infections.
Sterile API for injectable formulations targeting porcine staphylococcal pneumonia.
Low-irritation APIs for feline and canine dermatological pharmaceutical products.
Specialized pharmaceutical precursors for R&D in methicillin-resistant staphylococci.
Provision of API for broad-spectrum sanitizers used in staph-prone livestock housing.
Our manufacturing facility operates under Good Manufacturing Practice (GMP) guidelines, ensuring every gram of API is produced in a controlled environment.
Equipped with HPLC, GC-MS, and ICP-MS, we perform multi-stage validation to ensure zero contamination in anti-staphylococcal APIs.
End-to-end traceability from precursor sourcing to final delivery, maintaining a cold-chain if required for specific API stability.
Our commitment to purity is verified by independent global bodies across multiple continents.
Expert answers to common technical and commercial inquiries regarding our staphylococcus-fighting APIs.
Join 120+ global partners in eradicating staphylococcal infections with the world's most reliable pharmaceutical raw materials.
